ResearchIn-Press PreviewImmunologyVaccines Open Access | 10.1172/jci.insight.181067
1Vaccine & Immunotherapy Center, The Wistar Institute, Philadelphia, United States of America
2Virion Therapeutics, Newark, United States of America
Find articles by Hasanpourghadi, M. in: JCI | PubMed | Google Scholar
1Vaccine & Immunotherapy Center, The Wistar Institute, Philadelphia, United States of America
2Virion Therapeutics, Newark, United States of America
Find articles by Novikov, M. in: JCI | PubMed | Google Scholar
1Vaccine & Immunotherapy Center, The Wistar Institute, Philadelphia, United States of America
2Virion Therapeutics, Newark, United States of America
Find articles by Ambrose, R. in: JCI | PubMed | Google Scholar
1Vaccine & Immunotherapy Center, The Wistar Institute, Philadelphia, United States of America
2Virion Therapeutics, Newark, United States of America
Find articles by Chekaoui, A. in: JCI | PubMed | Google Scholar
1Vaccine & Immunotherapy Center, The Wistar Institute, Philadelphia, United States of America
2Virion Therapeutics, Newark, United States of America
Find articles by Newman, D. in: JCI | PubMed | Google Scholar
1Vaccine & Immunotherapy Center, The Wistar Institute, Philadelphia, United States of America
2Virion Therapeutics, Newark, United States of America
Find articles by Xiang, Z. in: JCI | PubMed | Google Scholar
1Vaccine & Immunotherapy Center, The Wistar Institute, Philadelphia, United States of America
2Virion Therapeutics, Newark, United States of America
Find articles by Luber, A. in: JCI | PubMed | Google Scholar
1Vaccine & Immunotherapy Center, The Wistar Institute, Philadelphia, United States of America
2Virion Therapeutics, Newark, United States of America
Find articles by Currie, S. in: JCI | PubMed | Google Scholar
1Vaccine & Immunotherapy Center, The Wistar Institute, Philadelphia, United States of America
2Virion Therapeutics, Newark, United States of America
Find articles by Zhou, X. in: JCI | PubMed | Google Scholar
1Vaccine & Immunotherapy Center, The Wistar Institute, Philadelphia, United States of America
2Virion Therapeutics, Newark, United States of America
Find articles by Ertl, H. in: JCI | PubMed | Google Scholar
Published September 3, 2024 - More info
In patients who progress from acute hepatitis B virus (HBV) infection to a chronic HBV (CHB) infection, CD8+ T cells fail to eliminate the virus and become impaired. A functional cure of CHB likely requires new and highly functional CD8+ T cell responses different from those induced by the infection. Here we report preclinical immunogenicity and efficacy of an HBV therapeutic vaccine that includes herpes simplex virus (HSV) glycoprotein D (gD), a checkpoint modifier of early T cell activation, that enhances, broadens, and prolongs CD8+ T cell responses. We developed a therapeutic HBV vaccine based on a chimpanzee adenovirus serotype 6 (AdC6) vector, called AdC6-gDHBV2, that targets conserved and highly immunogenic regions of the viral polymerase (pol) and core antigens fused into HSV gD. The vaccine was tested with, and without gD, in mice for immunogenicity and in an adeno-associated virus (AAV)8-1.3HBV vector model for antiviral efficacy. The vaccine encoding the HBV antigens within gD stimulates potent and broad CD8+ T cell responses. In a surrogate model of HBV infection, a single intramuscular (i.m.) injection of AdC6-gDHBV2 achieved significant and sustained declines of circulating HBV DNA copies (cps) and HBV surface antigen (HBsAg); both inversely correlated with HBV specific CD8+ T cell frequencies in spleens and livers. AdC6-gDHBV2 is the first therapeutic vaccine to show significant reductions in levels of HBV genome copies and HBsAg when used alone, even when vaccination was delayed for months from infection.